The joint venture, created through a collaboration with Bayer and CRISPR Therapeutics, will be based in Cambridge, MA.
On August 19, 2016, Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started operations in Cambridge, MA. In December 2015, Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop, and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. The two parties formally closed the transaction in the first quarter of 2016.
The joint venture has recently been incorporated as Casebia Therapeutics, a United Kingdom entity with its primary base of research operations in Cambridge. Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineering knowledge and relevant disease information through Bayer.
